Phase II evaluation of bleomycin. A Southwest Oncology Group study

Charles D. Haas; Charles A. Coltman; Jeffrey A. Gottlieb; Arthur Haut; James K. Luce; Robert W. Talley; Bohumil Samal; Henry E. Wilson; Barth Hoogstraten

doi:10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4

Phase II evaluation of bleomycin. A Southwest Oncology Group study

Charles D. Haas, Charles A. Coltman, Jeffrey A. Gottlieb, Arthur Haut, James K. Luce, Robert W. Talley, Bohumil Samal, Henry E. Wilson, Barth Hoogstraten

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m² was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.

Original language	English (US)
Pages (from-to)	8-12
Number of pages	5
Journal	Cancer
Volume	38
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4
State	Published - Jul 1976
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4

Cite this

@article{cb5a170340914e519ddc9cde1fa79d78,

title = "Phase II evaluation of bleomycin. A Southwest Oncology Group study",

abstract = "Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.",

author = "Haas, {Charles D.} and Coltman, {Charles A.} and Gottlieb, {Jeffrey A.} and Arthur Haut and Luce, {James K.} and Talley, {Robert W.} and Bohumil Samal and Wilson, {Henry E.} and Barth Hoogstraten",

year = "1976",

month = jul,

doi = "10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4",

language = "English (US)",

volume = "38",

pages = "8--12",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Phase II evaluation of bleomycin. A Southwest Oncology Group study

AU - Haas, Charles D.

AU - Coltman, Charles A.

AU - Gottlieb, Jeffrey A.

AU - Haut, Arthur

AU - Luce, James K.

AU - Talley, Robert W.

AU - Samal, Bohumil

AU - Wilson, Henry E.

AU - Hoogstraten, Barth

PY - 1976/7

Y1 - 1976/7

N2 - Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.

AB - Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.

UR - http://www.scopus.com/inward/record.url?scp=0017130075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017130075&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4

DO - 10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4

M3 - Article

C2 - 59628

AN - SCOPUS:0017130075

SN - 0008-543X

VL - 38

SP - 8

EP - 12

JO - Cancer

JF - Cancer

IS - 1

ER -

Phase II evaluation of bleomycin. A Southwest Oncology Group study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this